TianjinMay 25, 2026 /PRNewswire/ — From May 20 to 22, 2026, the 18th East-West Small Animal Clinical Veterinarian Conference was grandly held at the Tianjin Meijiang International Convention and Exhibition Center. Boehringer Ingelheim, a global leader in animal health, is deeply committed to preventive medicine, comprehensively showcasing its innovative product portfolio covering deworming, therapeutic drugs, and vaccines, along with digital solutions. Through continuous innovation and professional empowerment, the company assists veterinarians in enhancing diagnostic and treatment capabilities, fulfilling its commitment to safeguarding the lifelong health of pets.
Accelerating Transformation in Pet Healthcare, Prepared for Lifelong Health Protection
In recent years, as pets have gained higher status within families, their life cycles have significantly extended, with an increasingly evident trend toward aging. Against this backdrop, pet owners’ demands for pet health have expanded from mere “disease treatment” to comprehensive health management covering the entire life cycle—from youth to adulthood and old age—with growing attention to chronic disease management, geriatric care, and other long-term health issues.
Addressing industry pain points and clinical needs, Boehringer leverages its global R&D capabilities to continuously innovate, comprehensively covering the multi-disease, multi-scenario health needs of dogs and cats from youth to adulthood and old age. In the deworming field, the company offers efficient and reliable deworming solutions to meet veterinarians’ clinical needs: For dogs, a single dose of NexGard Spectra effectively addresses 15 key internal and external parasite issues. As a high-end oral dewormer for both internal and external parasites, it has become the same deworming product used by Chinese search and rescue dogs*, helping them maintain health and outstanding performance in high-intensity tasks such as natural disaster rescue and personnel search. For cats, the premium internal and external deworming solution Broadline® features a four-dimensional golden combination of ingredients and a specially designed small applicator. A single application prevents and treats 20 types of internal and external parasite indications. With a 0% alcohol, glycerol-based base that is gentle and low-irritation, it achieves “one application for internal and external protection.”
In the therapeutic field, Boehringer continues to expand its product portfolio related to chronic disease and geriatric management. It has launched Vetmedin® for treating canine heart disease, Semintra® for feline chronic kidney disease, and Metacam® and Previcox® for managing pain and inflammation in dogs and cats, extending their lives and improving quality of life. Additionally, immune-related products such as Rabisin® and Eurican® meet routine clinical immunization needs for dogs and cats. This diverse product portfolio achieves comprehensive coverage from prevention to treatment across the entire life cycle.
Behind this innovation lies sustained investment in R&D. In 2025, Boehringer invested 500 million euros in global animal health R&D, accounting for over 10% of the business segment’s total revenue. The world’s first oral liquid drug for treating feline diabetes, Senvelgo®, is being accelerated for introduction into China. This SGLT2 inhibitor conveniently controls blood glucose in cats with once-daily dosing, potentially addressing unmet medical needs in the domestic animal health field.
R&D Experts and Clinical Practice on the Same Stage: Broadline® Mini-Class Interprets the Exclusive Deworming Essence for Cats
During the conference, Boehringer officially announced the exclusive deworming essence concept for Broadline®, demonstrating innovation-driven success with empirical evidence. Professor Frederic Beugnet, Boehringer’s global technical director for deworming products and “father of Broadline®,” personally attended the event. Drawing on global R&D experience, he unveiled the secrets of Broadline® deworming essence: Through a four-dimensional golden combination of ingredients, the product prevents and treats 20 common parasite indications in cats, including tapeworm infections easily caused by raw meat-based diets. Broadline®‘s unique human-grade packaging applicator design achieves a breakthrough in maintaining ingredient stability and preventing impurity precipitation. Niu Zilun, Head of Boehringer Ingelheim’s Companion Animal Business in China, shared the advantages of the product’s 0% alcohol, gentle texture from the perspectives of veterinary clinical practice and pet owner experience. He also demonstrated the three-step deworming essence technique of “twist, push, and comb,” fully showcasing Broadline® as a newly innovated and upgraded exclusive deworming essence for cats, from ingredients to user experience.
Professional Training + Innovative Tools: Empowering Veterinarians to Promote Industry Development
Beyond its comprehensive product matrix and ongoing technological R&D, Boehringer recognizes the importance of veterinarian training and education. It is making efforts in multiple areas, including technical support, veterinary education, and digital tools, to help veterinarians enhance diagnostic and treatment capabilities and engage pet owners in building a closed-loop health management system for the entire life cycle.
Since its establishment in 2014, the Boehringer Academy has focused on the professional growth of clinical veterinarians, building a comprehensive training platform. It conducts approximately 80 online and offline training sessions annually, covering specialized fields such as feline medicine, cardiology, and dentistry. Each year, about 10,000 clinical veterinarians and management personnel participate in the training, effectively reaching veterinarians across various regions in China.
At the same time, the company actively develops digital tools for clinical application, supporting the enhancement of veterinary diagnostic capabilities and long-term standardized management of chronic diseases. For example, the HEART X systematic training tool, specifically developed for veterinarians, targets improvements in cardiology diagnostic and treatment capabilities. To strengthen the connection between pet owners and veterinarians, the company has launched a Resting Respiratory Rate mini-program, enabling pet owners to conduct home monitoring and data recording, assisting in assessing heart disease progression, and promoting efficient communication with veterinarians, forming a closed loop of “diagnosis + treatment + home-based long-term management.” Additionally, the company continues to promote the development of specialized fields within the industry, taking the lead in formulating and implementing expert consensus on feline heart disease diagnosis and treatment, combining international cutting-edge standards with Chinese clinical practice to help veterinarians establish more standardized and unified diagnostic and treatment approaches.
Niu Zilun, Head of Boehringer Ingelheim’s Companion Animal Business in China, stated: “We always prioritize the lifelong health management of pets as our core focus. Through continuous innovation, we actively build a product system and veterinarian empowerment framework covering prevention, treatment, and long-term management needs, helping to elevate the level of clinical diagnosis and treatment for pets in China. In the future, the company will further accelerate the introduction of global innovative products into China, deepen cooperation with all industry stakeholders, and provide practical and sustainable prevention and health management practices for China’s pet healthcare industry, assisting veterinarians in more effectively safeguarding pet health in clinical settings.”
*Chinese search and rescue dogs refer to Zixie, Doubao, and Zhurong.